Feature | March 19, 2013 | Gregory M. Eckel, M.D.

Understanding the Breast Biopsy Evaluation Process

DNA confirmation helps reduce medical errors and ensures proper patient care

As a result of routine mammography screening, approximately 1.6 million breast biopsies are performed annually to determine whether a suspicious lesion is malignant or benign. Of these 1.6 million biopsies, approximately 20 percent will result in a positive cancer diagnosis.[1] These numbers are staggering alone, and are just the statistics for one out of more than 200 types of cancers. As radiologists, we strive to provide our patients with the best medical care available, but what we do not always think about is what happens after a sample leaves our office. Errors that occur in the biopsy diagnostic process are specific diagnostic errors that imaging professionals must address. 

A Complex Process

Imaging professionals are often one of the first points of contact for patients during the biopsy process, but certainly are not the last. Within the biopsy process the most common errors involve the specimen being mislabeled or contaminated during the routine biopsy evaluation process. These potential errors are referred to as specimen provenance complications (SPCs). However, the possibility for human error is present at every stage of this process, especially since several different people are involved and many steps take place in separate locations. 

After biopsy sample is taken, the tissue sample moves through a complex 18-step process, no matter if an internal or reference lab is used. In the pre-analytic phase, specimens are collected, labeled, transported and accessioned into the pathology lab. The next step is the analytic phase, where the specimens are examined grossly, dissected and prepared for analysis. This involves placing them into cassettes, which are then processed through a chemical bath that produces a final wax tissue block. A small cut of tissue from the block is then placed on a slide. Finally, in the post analytic phase, the slides are delivered to the pathologist for review, along with the accompanying paperwork for each patient. 

Given the complex nature of the diagnostic testing cycle, and the potentially devastating ramifications of incorrect diagnosis, preventing diagnostic mistakes due to SPCs is crucial for the medical staff involved in the biopsy process and the patient.

How Often Does This Happen?

It is estimated that approximately 1 percent of all surgical biopsies are subject to undetected tissue transposition or contamination, which could lead to a cancer diagnosis being assigned to the wrong patient, ultimately leading to inappropriate or delayed treatment. These events not only result in harm to patients, but often have serious legal implications for the healthcare providers responsible for the error. Anecdotally, I have heard of several such instances from colleagues over the years.

DNA’s Role in the Evaluation Process

At Women’s Breast Center in Santa Monica, Calif., the Know Error system is used for breast biopsies, which has added minimal disruption to the practice’s standard processes. At the time of the biopsy procedure, a buccal swab of the patient’s cheek is taken to obtain a DNA reference sample. Then the swab is sent to an independent DNA laboratory. The biopsy tissue samples are collected as usual, then placed in bar-coded specimen containers matching that of the buccal swab, and sent to the pathology lab for evaluation. If a malignancy is found in a biopsy sample, a DNA specimen provenance assignment (DSPA) test is completed to compare the DNA profiles of the biopsy tissue and DNA reference sample. Concurrence of these profiles allows for absolute confirmation of patient identity, and is imperative before any diagnosis or treatment course is rendered. Since implementing the DSPA program, our staff has helped ensure that the many women who receive biopsies at our practice are getting the most accurate information possible.

Adding this DNA confirmation — or taking a DNA timeout — completes the diagnostic testing cycle and protects radiologists and patients alike.
Moreover, the power of DNA confirmation reduces unnecessary medical errors and helps fulfill the promise we provide to our patients who entrust us with their care. 
itn

Gregory Eckel, M.D., is the chief of breast intervention at Harbor UCLA Medical Center, an associate clinical professor of radiology at UCLA, and a clinical breast radiologist at the Women’s Breast Center in Santa Monica, Calif.

Reference

1. Silverstein, M.J., et al. “Image-detected breast cancer: State of the art diagnosis and treatment. “ J Am Coll Surg 2005; 201(4), 586-597.

Related Content

Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Lung Decision Precision
News | Lung Cancer | June 04, 2018
For smokers and former smokers, the threat of lung cancer always lurks in the shadows.
Metal artifact reduction led to a 20 percent increase in the planning target volume (PTV) in this prostate cancer case from Henry Ford Health System. The volume of the healthy bladder tissue to be spared was also reduced by 4 percent.

Metal artifact reduction led to a 20 percent increase in the planning target volume (PTV) in this prostate cancer case from Henry Ford Health System. The volume of the healthy bladder tissue to be spared was also reduced by 4 percent.

Feature | Computed Tomography (CT) | May 03, 2018 | By Jeff Zagoudis
Computed tomography (CT) has long been the standard of care for imaging to plan radiation therapy (RT) treatments. 
MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

Feature | Proton Therapy | March 06, 2018 | By Jeff Zagoudis
Proton therapy has experienced major growth in the last decade, but that growth seems to have slowed slightly in recent...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.

This PET/CT shows metastasis of tumors, taken with the Philips TruFlight Select.

Feature | Radiation Oncology | January 31, 2018 | By Emily Clemons
Technological and scientific advances in radiation oncology are allowing practitioners to put patients first in...
Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Sam Hancock, Ph.D.

Sam Hancock, Ph.D.

Sponsored Content | Case Study | Radiation Oncology | November 06, 2017
In establishing the new Southeast Cancer Center (Cape Girardeau, Mo.), clinic officials not only had the opportunity to...
Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH
Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the...
Videos | Women's Health | October 23, 2017
William Hall, M.D., radiation oncologist in the Department of Radiation Oncology at PeaceHealth St. Joseph Medical...
Overlay Init